ES2525593T3 - Métodos y compuestos de producción de inhibidores de la dipeptidil peptidasa IV e intermedios de los mismos - Google Patents

Métodos y compuestos de producción de inhibidores de la dipeptidil peptidasa IV e intermedios de los mismos Download PDF

Info

Publication number
ES2525593T3
ES2525593T3 ES12162626.1T ES12162626T ES2525593T3 ES 2525593 T3 ES2525593 T3 ES 2525593T3 ES 12162626 T ES12162626 T ES 12162626T ES 2525593 T3 ES2525593 T3 ES 2525593T3
Authority
ES
Spain
Prior art keywords
intermediates
inhibitors
compounds
production
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES12162626.1T
Other languages
English (en)
Inventor
Truc Chi Vu
Rita Fox
Ronald L. Hanson
John A. Mazzullo, Jr.
Jianji Wang
Jurong Yu
David R. Magnin
Lawrence G. Hamann
David B. Brzozowski
Jollie Duaine Godfrey, Jr.
Sergei V. Kolotuchin
Ramesh N. Patel
Kwok Wong
Jason Zhu
David J. Augeri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32507798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2525593(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2525593T3 publication Critical patent/ES2525593T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/02—Saturated compounds containing hydroxy or O-metal groups
    • C07C62/06—Saturated compounds containing hydroxy or O-metal groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/63—Halogen-containing esters of saturated acids
    • C07C69/635—Halogen-containing esters of saturated acids containing rings in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto que tiene una estructura como se muestra en la Fórmula IV más abajo:**Fórmula**

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31
imagen32
imagen33
imagen34
imagen35
imagen36
imagen37
imagen38
imagen39
imagen40
imagen41

Claims (1)

  1. imagen1
    imagen2
ES12162626.1T 2002-12-09 2003-12-04 Métodos y compuestos de producción de inhibidores de la dipeptidil peptidasa IV e intermedios de los mismos Expired - Lifetime ES2525593T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43181402P 2002-12-09 2002-12-09
US431814P 2002-12-09

Publications (1)

Publication Number Publication Date
ES2525593T3 true ES2525593T3 (es) 2014-12-26

Family

ID=32507798

Family Applications (4)

Application Number Title Priority Date Filing Date
ES12162633.7T Expired - Lifetime ES2526138T3 (es) 2002-12-09 2003-12-04 Métodos y compuestos de producción de inhibidores de la dipeptidil peptidasa IV e intermedios de los mismos
ES12162626.1T Expired - Lifetime ES2525593T3 (es) 2002-12-09 2003-12-04 Métodos y compuestos de producción de inhibidores de la dipeptidil peptidasa IV e intermedios de los mismos
ES03812799.9T Expired - Lifetime ES2484915T3 (es) 2002-12-09 2003-12-04 Procedimientos y compuestos de producción de inhibidores de la dipeptidil peptidasa IV e intermedios de los mismos
ES12162624.6T Expired - Lifetime ES2494793T3 (es) 2002-12-09 2003-12-04 Procedimientos y compuestos de producción de inhibidores de la dipeptidil peptidasa IV e intermedios de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES12162633.7T Expired - Lifetime ES2526138T3 (es) 2002-12-09 2003-12-04 Métodos y compuestos de producción de inhibidores de la dipeptidil peptidasa IV e intermedios de los mismos

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES03812799.9T Expired - Lifetime ES2484915T3 (es) 2002-12-09 2003-12-04 Procedimientos y compuestos de producción de inhibidores de la dipeptidil peptidasa IV e intermedios de los mismos
ES12162624.6T Expired - Lifetime ES2494793T3 (es) 2002-12-09 2003-12-04 Procedimientos y compuestos de producción de inhibidores de la dipeptidil peptidasa IV e intermedios de los mismos

Country Status (17)

Country Link
US (4) US7420079B2 (es)
EP (5) EP2517706B1 (es)
JP (6) JP4886193B2 (es)
KR (1) KR20050088309A (es)
CN (3) CN102942482B (es)
AU (1) AU2003297647A1 (es)
BR (1) BR0317139A (es)
CA (1) CA2508619A1 (es)
DK (4) DK2517706T3 (es)
ES (4) ES2526138T3 (es)
IL (1) IL192912A0 (es)
MX (1) MXPA05005970A (es)
PL (1) PL377123A1 (es)
PT (4) PT1581487E (es)
SI (4) SI2505579T1 (es)
TW (2) TW200512191A (es)
WO (1) WO2004052850A2 (es)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0487425A (ja) * 1990-07-31 1992-03-19 Fujitsu Ltd 回線切り替え装置
US7420079B2 (en) * 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
US6995183B2 (en) * 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
JP2007511487A (ja) 2003-11-17 2007-05-10 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼｉｖ阻害剤の使用
US20080038341A1 (en) 2004-01-20 2008-02-14 James Kowalski Direct Compression Formulation And Process
TW200538122A (en) * 2004-03-31 2005-12-01 Bristol Myers Squibb Co Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein
US7741082B2 (en) * 2004-04-14 2010-06-22 Bristol-Myers Squibb Company Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
TW200536827A (en) * 2004-05-04 2005-11-16 Bristol Myers Squibb Co Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors
US7214702B2 (en) * 2004-05-25 2007-05-08 Bristol-Myers Squibb Company Process for producing a dipeptidyl peptidase IV inhibitor
DE102004035978A1 (de) * 2004-07-23 2006-03-16 Justus-Liebig-Universität Giessen Aminoadamantan-Verbindungen
US20060035954A1 (en) * 2004-08-11 2006-02-16 Sharma Padam N Ammonolysis process for the preparation of intermediates for DPP IV inhibitors
WO2006034175A1 (en) * 2004-09-17 2006-03-30 Albemarle Corporation Synthesis process for 2-(3-hydroxy-1-adamantyl)-2-oxoacetic acid
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
WO2006107963A2 (en) * 2005-04-06 2006-10-12 Novartis Ag Process for preparing dipeptide amides
US7205432B2 (en) * 2005-05-31 2007-04-17 Kemfine Oy Process for the preparation of adamantane derivatives
FI120765B (fi) * 2005-05-31 2010-02-26 Kemfine Group Ltd Menetelmä adamantaanijohdannaisten valmistamiseksi
MY152185A (en) 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
PL1942898T5 (pl) 2005-09-14 2014-10-31 Takeda Pharmaceuticals Co Inhibitory peptydazy dipeptydylowej do leczenia cukrzycy
CN102675221A (zh) 2005-09-16 2012-09-19 武田药品工业株式会社 用于制备嘧啶二酮衍生物的方法中的中间体
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
JP2009533393A (ja) 2006-04-12 2009-09-17 プロビオドルグ エージー 酵素阻害薬
JP5272324B2 (ja) * 2006-04-17 2013-08-28 住友化学株式会社 Ｎ−ｔｅｒｔ−ブトキシカルボニル−２−ピロリジノン類およびその製造方法
WO2007122745A1 (ja) * 2006-04-17 2007-11-01 Sumitomo Chemical Company, Limited Ｎ−ｔｅｒｔ−ブトキシカルボニル−２−ピロリジノン類およびその製造方法
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
RU2010103104A (ru) 2007-07-02 2011-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные имидазола в качестве антагонистов рецептора ccr2
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
US8338450B2 (en) * 2007-09-21 2012-12-25 Lupin Limited Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
PE20110297A1 (es) 2008-08-15 2011-05-26 Boehringer Ingelheim Int Inhibidores de dpp-4 para la cicatrizacion de heridas
US20100124541A1 (en) * 2008-11-19 2010-05-20 Auspex Pharmaceuticals, Inc. Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TWI466672B (zh) 2009-01-29 2015-01-01 Boehringer Ingelheim Int 小兒科病人糖尿病之治療
WO2010092125A1 (en) 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
NZ594044A (en) 2009-02-13 2014-08-29 Boehringer Ingelheim Int Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
CA2756786A1 (en) 2009-03-27 2010-09-30 Bristol-Myers Squibb Company Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2012523235A (ja) * 2009-04-08 2012-10-04 ブリストル−マイヤーズ スクイブ カンパニー Ｐｄｈおよびｆｄｈ酵素を発現する遺伝学的に安定なプラスミド
KR20120006047A (ko) * 2009-04-09 2012-01-17 산도즈 아게 삭사글립틴의 결정 형태
US8748457B2 (en) 2009-06-18 2014-06-10 Lupin Limited 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
FR2956400A1 (fr) 2010-02-15 2011-08-19 Finorga Procede de preparation de composes adamantyles
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
DK2545047T3 (da) 2010-03-10 2014-07-28 Probiodrug Ag Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5)
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
EP2368874A1 (en) 2010-03-26 2011-09-28 Sandoz AG Racemisation of (R)-N-Boc-3-hydroxyadamant-1-yl glycine
MX2012011631A (es) 2010-04-06 2013-01-18 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
KR20130038258A (ko) 2010-05-05 2013-04-17 아시아 케미컬 인더스트리스 리미티드 삭사글립틴 중간체, 삭사글립틴 다형 및 이들의 제조 방법
EP3366304B1 (en) 2010-06-24 2020-05-13 Boehringer Ingelheim International GmbH Diabetes therapy
CN103370064A (zh) 2010-09-03 2013-10-23 百时美施贵宝公司 使用水溶性抗氧化剂的药物制剂
WO2012028721A1 (en) 2010-09-03 2012-03-08 Sandoz Ag PROCESS FOR THE REDUCTIVE AMINATION OF α-KETO CARBOXYLIC ACIDS
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
CA2812699A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2608788A1 (en) 2010-10-04 2013-07-03 Assia Chemical Industries Ltd. Polymorphs of saxagliptin hydrochloride and processes for preparing them
MX2013008372A (es) 2011-02-01 2013-08-12 Astrazeneca Uk Ltd Formulaciones farmaceuticas que incluyen compuesto de amina.
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012162507A1 (en) 2011-05-24 2012-11-29 Apicore, Llc Process for preparing saxagliptin and its novel intermediates useful in the synthesis thereof
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JPWO2013081100A1 (ja) * 2011-11-30 2015-04-27 積水メディカル株式会社 アダマンチルヒダントイン化合物
ITMI20120842A1 (it) * 2012-05-16 2013-11-17 Chemelectiva S R L Intermedi utili per la preparazione di saxagliptina e processo per la loro preparazione
WO2013175395A2 (en) * 2012-05-21 2013-11-28 Dr. Reddys Laboratories Limited Improved process for preparation of saxagliptin and its salts
US8664443B2 (en) 2012-05-23 2014-03-04 Divi's Laboratories Ltd. Process for the preparation of (1S, 3S, 5S)-2-[2(S)-2-amino-2-(3-hydroxy-1-adamantan-1-yl) acetyl]-2-azabicyclo [3.1.0] hexane-3-carbonitrile
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2013175297A1 (en) 2012-05-24 2013-11-28 Apotex Pharmachem India Pvt. Ltd Salts of saxagliptin with organic acids
AU2013285078A1 (en) 2012-07-02 2015-01-29 Sun Pharmaceutical Industries Limited Saxagliptin salts
CN103539724B (zh) * 2012-07-12 2017-09-26 博瑞生物医药（苏州）股份有限公司 沙格列汀单一立体异构体的新晶型和纯化方法
WO2014057495A1 (en) 2012-10-11 2014-04-17 Lee Pharma Limited A process for industrial preparation of [(s)-n-tert butoxycarbonyl-3-hydroxy]adamantylglycine
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
WO2014108830A1 (en) 2013-01-10 2014-07-17 Wockhardt Limited A process for preparing pharmaceutically acceptable salt of saxagliptin
CN104098481B (zh) * 2013-04-10 2016-05-11 浙江九洲药物科技有限公司 一种沙格列汀中间体的制备方法
CN103265473A (zh) * 2013-06-04 2013-08-28 上海同昌生物医药科技有限公司 一种生产沙格列汀的方法
CN104370769B (zh) * 2013-08-14 2017-05-31 重庆博腾制药科技股份有限公司 一种制备羟基金刚烷甘氨酸衍生物的方法
WO2015031595A1 (en) * 2013-08-28 2015-03-05 Amneal Pharmaceuticals Llc A process for preparation of saxagliptin and its hydrochloride salt
CN103450071A (zh) * 2013-09-05 2013-12-18 南京工业大学 一种医药中间体2-氮杂双环[3.1.0]己烷-2,3-二碳酸叔丁酯的不对称合成方法
CN103450073A (zh) * 2013-09-09 2013-12-18 嘉兴学院 具有环丙烷结构r-二苯基脯氨醇类手性有机小分子化合物及其合成方法
CN103467361A (zh) * 2013-09-09 2013-12-25 嘉兴学院 具有环丙烷结构s-脯氨酸的吗啉衍生物及其制备方法
CN103450074A (zh) * 2013-09-09 2013-12-18 嘉兴学院 具有环丙烷结构的r-脯氨醇手性有机小分子化合物及其合成方法
CN103467362A (zh) * 2013-09-09 2013-12-25 嘉兴学院 具有环丙烷结构s-二苯基脯氨醇类手性有机小分子化合物及其合成方法
CN103467360A (zh) * 2013-09-09 2013-12-25 嘉兴学院 具有环丙烷结构r-脯氨酸的吗啉衍生物及其制备方法
CN103435536A (zh) * 2013-09-09 2013-12-11 嘉兴学院 具有环丙烷结构s-脯氨酸的吡咯衍生物及其制备方法
CN103435534A (zh) * 2013-09-09 2013-12-11 嘉兴学院 具有环丙烷结构s-脯氨酸的制备方法
CN103435533A (zh) * 2013-09-09 2013-12-11 嘉兴学院 具有环丙烷结构的s-脯氨醇手性有机小分子化合物及其合成方法
CN103435535A (zh) * 2013-09-09 2013-12-11 嘉兴学院 具有环丙烷结构r-脯氨酸的制备方法
CN104649953A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 一种沙格列汀倍半水合物化合物
WO2015087262A1 (en) 2013-12-11 2015-06-18 Ranbaxy Laboratories Limited Process for the preparation of saxagliptin and its intermediates
CN104829444A (zh) * 2014-02-12 2015-08-12 上海医药工业研究院 一种α-溴代三环[3.3.1.13,7]癸烷-1-乙酸的后处理方法
CN103910669B (zh) * 2014-04-04 2015-10-21 苏州景泓生物技术有限公司 沙格列汀关键中间体的制备方法
CN103951588B (zh) * 2014-04-30 2016-10-05 淮海工学院 一种合成沙格列汀中间体n-叔丁氧羰基-3-羟基-1-金刚烷基-d-甘氨酸的方法
CN104109100A (zh) * 2014-05-29 2014-10-22 上海应用技术学院 一种金刚烷氨基酸酯化合物的合成方法
CN105315189A (zh) * 2014-05-29 2016-02-10 上海医药工业研究院 一种制备（5s）-5-氨基羰基-4,5-二氢-1h-吡咯-1-羧酸-1（1,1-二甲基乙基）酯的方法
CN104098487A (zh) * 2014-07-31 2014-10-15 天津民祥生物医药科技有限公司 一种n-叔丁氧羰基-3-羟基-1-金刚烷基甘氨酸的制备方法
CN104098505A (zh) * 2014-07-31 2014-10-15 天津民祥生物医药科技有限公司 一种沙格列汀的制备方法
WO2016026827A1 (en) * 2014-08-20 2016-02-25 Sandoz Ag Crystalline boc-s-hadgly and process for its preparation
CN104293844B (zh) * 2014-08-26 2017-10-10 苏州永健生物医药有限公司 一种特拉匹韦中间体的合成方法
GB201415598D0 (en) 2014-09-03 2014-10-15 Univ Birmingham Elavated Itercranial Pressure Treatment
CN105503698A (zh) * 2014-09-26 2016-04-20 深圳翰宇药业股份有限公司 一种合成沙格列汀及其中间体的方法
CA2979033A1 (en) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
CN104817476B (zh) * 2015-03-25 2020-09-11 重庆医科大学 一种制备非天然氨基酸的方法
CN105037245B (zh) * 2015-08-03 2017-04-12 沧州那瑞化学科技有限公司 一种沙格列汀中间体的制备方法
CN105112469B (zh) * 2015-09-24 2018-07-27 福建省微生物研究所 酶催化不对称转氨基反应制备沙格列汀手性中间体的方法
CN106554301B (zh) * 2015-09-30 2018-09-21 深圳翰宇药业股份有限公司 一种沙格列汀关键中间体的制备方法
KR101715682B1 (ko) 2015-10-29 2017-03-13 경동제약 주식회사 삭사글립틴의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 삭사글립틴의 제조방법
DE102016116130A1 (de) 2016-08-30 2018-03-01 Universität Bielefeld Verfahren zur Herstellung chiraler Aminonitrile
US11253508B2 (en) 2017-04-03 2022-02-22 Coherus Biosciences, Inc. PPARy agonist for treatment of progressive supranuclear palsy
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN112567468A (zh) 2018-06-14 2021-03-26 阿斯利康(英国)有限公司 用二肽基肽酶-4抑制剂药物组合物降低血糖的方法
CN113330021A (zh) * 2019-01-24 2021-08-31 帝斯曼知识产权资产管理有限公司 肽沉淀方法
CN111170927B (zh) * 2020-04-10 2020-08-04 上海翰森生物医药科技有限公司 一种沙格列汀中间体的制备方法
CN114621068A (zh) * 2022-03-31 2022-06-14 沧州那瑞化学科技有限公司 3-羟基-1-金刚烷甲基酮的制备方法及合成沙格列汀的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3325478A (en) * 1964-11-17 1967-06-13 Du Pont alpha-amino-1-adamantylmethyl penicillins
US3646066A (en) * 1970-03-25 1972-02-29 Squibb & Sons Inc Adamantylamino-tetrahydronaphthyl-oxypropanols and ester derivatives
SU910605A1 (ru) * 1980-06-23 1982-03-07 Киевский Ордена Ленина Политехнический Институт Им.50-Летия Великой Октябрьской Социалистической Революции Способ получени @ -амино-1-адамантилуксусной кислоты
EP0140503A1 (en) 1983-08-16 1985-05-08 Genentech, Inc. An efficient process for preparing L-amino acids in bacteria
JPS62200861A (ja) 1986-02-28 1987-09-04 Toshiba Corp 画像形成装置
JPH06102027B2 (ja) * 1987-08-13 1994-12-14 財団法人相模中央化学研究所 Ｌ−２−アミノ−４−フェニル酪酸の製造方法
CA2008702A1 (en) 1989-02-27 1990-08-27 Ronald L. Hanson Process for transformation of hydroxyketo acids to hydroxyamino acids
IL120873A0 (en) 1996-05-24 1997-09-30 Tanabe Seiyaku Co Process for preparing optically active 2-halogen-3-hydroxypropionic acid ester
US6093330A (en) 1997-06-02 2000-07-25 Cornell Research Foundation, Inc. Microfabrication process for enclosed microstructures
US6068991A (en) 1997-12-16 2000-05-30 Bristol-Myers Squibb Company High expression Escherichia coli expression vector
KR20010071908A (ko) 1998-07-15 2001-07-31 스티븐 비. 데이비스 케톤의 입체 선택적인 환원적 아민화
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
JP3942846B2 (ja) * 2001-06-21 2007-07-11 独立行政法人科学技術振興機構 組織特異的トランスポーター阻害剤
WO2004037181A2 (en) 2002-10-23 2004-05-06 Bristol-Myers Squibb Company Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
US7420079B2 (en) * 2002-12-09 2008-09-02 Bristol-Myers Squibb Company Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
JP2007511487A (ja) 2003-11-17 2007-05-10 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼｉｖ阻害剤の使用
TW200538122A (en) 2004-03-31 2005-12-01 Bristol Myers Squibb Co Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein
US7741082B2 (en) 2004-04-14 2010-06-22 Bristol-Myers Squibb Company Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
TW200536827A (en) 2004-05-04 2005-11-16 Bristol Myers Squibb Co Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors
US7214702B2 (en) 2004-05-25 2007-05-08 Bristol-Myers Squibb Company Process for producing a dipeptidyl peptidase IV inhibitor

Also Published As

Publication number Publication date
US8278462B2 (en) 2012-10-02
EP2505578B1 (en) 2014-09-24
SI2505578T1 (sl) 2014-12-31
AU2003297647A1 (en) 2004-06-30
EP2505578A2 (en) 2012-10-03
EP2505579B1 (en) 2014-11-05
EP1581487A2 (en) 2005-10-05
CN102070451B (zh) 2015-07-15
KR20050088309A (ko) 2005-09-05
EP2505579A3 (en) 2013-08-07
EP2517706A2 (en) 2012-10-31
JP5730341B2 (ja) 2015-06-10
IL192912A0 (en) 2009-02-11
JP5860007B2 (ja) 2016-02-16
JP2006516121A (ja) 2006-06-22
MXPA05005970A (es) 2005-08-18
US20090018311A1 (en) 2009-01-15
DK1581487T3 (da) 2014-07-28
JP4886193B2 (ja) 2012-02-29
PL377123A1 (pl) 2006-01-23
ES2484915T3 (es) 2014-08-12
CN1791401B (zh) 2012-10-03
SI2505579T1 (sl) 2015-01-30
PT2517706E (pt) 2014-09-05
US7420079B2 (en) 2008-09-02
US7705033B2 (en) 2010-04-27
CN1791401A (zh) 2006-06-21
BR0317139A (pt) 2005-11-29
JP2013153748A (ja) 2013-08-15
CN102942482B (zh) 2015-11-18
EP1581487A4 (en) 2007-08-08
EP2517706B1 (en) 2014-06-25
JP5511582B2 (ja) 2014-06-04
CA2508619A1 (en) 2004-06-24
US20100274025A1 (en) 2010-10-28
EP2792672A2 (en) 2014-10-22
DK2505579T3 (en) 2015-01-19
PT2505579E (pt) 2015-01-02
WO2004052850A2 (en) 2004-06-24
ES2526138T3 (es) 2015-01-07
WO2004052850A3 (en) 2006-03-02
DK2505578T3 (en) 2014-12-08
JP2011006440A (ja) 2011-01-13
EP2792672A3 (en) 2014-11-26
JP2011006441A (ja) 2011-01-13
US20130012723A1 (en) 2013-01-10
TW200512191A (en) 2005-04-01
SI2517706T1 (sl) 2014-09-30
SI1581487T1 (sl) 2014-09-30
JP5345986B2 (ja) 2013-11-20
ES2494793T3 (es) 2014-09-16
JP2014012689A (ja) 2014-01-23
JP2016040282A (ja) 2016-03-24
DK2517706T3 (da) 2014-09-08
CN102942482A (zh) 2013-02-27
PT2505578E (pt) 2014-12-17
US20050090539A1 (en) 2005-04-28
PT1581487E (pt) 2014-09-08
EP2505578A3 (en) 2013-07-31
TW200914419A (en) 2009-04-01
EP1581487B1 (en) 2014-06-04
CN102070451A (zh) 2011-05-25
EP2505579A2 (en) 2012-10-03
EP2517706A3 (en) 2013-03-20

Similar Documents

Publication Publication Date Title
ES2525593T3 (es) Métodos y compuestos de producción de inhibidores de la dipeptidil peptidasa IV e intermedios de los mismos
ECSP055886A (es) Derivados de isoindolina
ES2548578T3 (es) Monosebacato de un derivado de pirazol
EA200500201A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
ES2518316T3 (es) Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia
AU2003282983A8 (en) Glycinenitrile-based inhibitors of dipeptidyl peptidase iv and methods
AR056764A1 (es) Aminopirimidinas utiles como inhibidores de quinasa
NI200500031A (es) Nuevos procesos para la sintesis de ivabradine y ademas sales que la contienen con un acido aceptable farmaceuticamente.
UY34969A (es) Síntesis de compuestos de ester y ácido bórico
ECSP088550A (es) Nuevos compuestos que son inhibidores de erk
ECSP099781A (es) Novedosos compuestos que son inhibidores de erk
CR10636A (es) Inhibidor de quinasa
CY1105826T1 (el) Μεθοδος συνθεσης του (1s)-4,5-διμεθοξυ-1-(μεθυλαμινομεθυλ)βενζοκυκλοβουτανιου και των αλατων προσθηκης αυτου και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης αυτης με φαρμακευτικως αποδεκτο οξυ
GT200500354A (es) Metodo para preparar n-fenilpirazol-1-carboxamidas
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
ATE440833T1 (de) Antithrombotische diamide
CO5720995A2 (es) Compuesto novedoso
AR053989A1 (es) Compuestos espiro-hidantoina sustituidos con piridilo. composiciones farmaceuticas y procesos de obtencion.
EA200500690A1 (ru) Новые соединения пиридопиримидинона, способ их получения и фармацевтические композиции, которые их содержат
AR064369A1 (es) Compuestos derivados de piperidina o sales aceptables para uso farmaceutico de los mismos.
EA200500204A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
EA200500683A1 (ru) Новые соединения пирролидина и тиазолидина, способ их получения и фармацевтические композиции, которые их содержат
EA200600898A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
UY28653A1 (es) N-alquil pirroles como inhibidores de la hmg-coa reductasa
UY28089A1 (es) Compuestos calciliticos